Cargando…
Survey of the current status of subclinical coronavirus disease 2019 (COVID-19)
OBJECTIVES: We investigated relationships between subclinical COVID-19 (coronavirus disease 2019) and background factors. METHODS: We determined SARS-CoV-2 antibody (IgG) prevalence in 1603 patients, doctors, and nurses in 65 medical institutions in Kanagawa Prefecture, Japan and investigated their...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474902/ https://www.ncbi.nlm.nih.gov/pubmed/32958395 http://dx.doi.org/10.1016/j.jiac.2020.09.005 |
_version_ | 1783579413190803456 |
---|---|
author | Matsuba, Ikuro Hatori, Nobuo Koido, Norihiko Watanabe, Yoshiyuki Ebara, Futoshi Matsuzawa, Yoko Nishikawa, Tetsuo Kunishima, Tomoyuki Degawa, Hisakazu Nishikawa, Masanori Ono, Yoshiaki Kanamori, Akira |
author_facet | Matsuba, Ikuro Hatori, Nobuo Koido, Norihiko Watanabe, Yoshiyuki Ebara, Futoshi Matsuzawa, Yoko Nishikawa, Tetsuo Kunishima, Tomoyuki Degawa, Hisakazu Nishikawa, Masanori Ono, Yoshiaki Kanamori, Akira |
author_sort | Matsuba, Ikuro |
collection | PubMed |
description | OBJECTIVES: We investigated relationships between subclinical COVID-19 (coronavirus disease 2019) and background factors. METHODS: We determined SARS-CoV-2 antibody (IgG) prevalence in 1603 patients, doctors, and nurses in 65 medical institutions in Kanagawa Prefecture, Japan and investigated their background factors. Antibodies (IgG) against SARS-CoV-2 were analyzed by Immunochromatographic test. RESULTS: The 39 subjects (2.4%) were found to be IgG antibody-positive: 29 in the patient group (2.9%), 10 in the doctor/nurse group (2.0%), and 0 in the control group. After adjustment for age, sex, and the antibody prevalence in the control group, antibody prevalence was 2.7% in the patient group and 2.1% in the doctor/nurse group. There was no significant difference between the antibody-positive subjects and the antibody-negative subjects in any background factors investigated including overseas travel, contact with overseas travelers, presence/absence of infected individuals in the living area, use of trains 5 times a week or more, BCG vaccination, and use of ACE inhibitor and ARB. CONCLUSIONS: Antibody prevalence in the present survey at medical institution is higher than that in Tokyo and in Osaka measured by the government suggesting that subclinical infections are occurring more frequently than expected. No background factor that influenced antibody-positive status due to subclinical infection was identified. |
format | Online Article Text |
id | pubmed-7474902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74749022020-09-08 Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) Matsuba, Ikuro Hatori, Nobuo Koido, Norihiko Watanabe, Yoshiyuki Ebara, Futoshi Matsuzawa, Yoko Nishikawa, Tetsuo Kunishima, Tomoyuki Degawa, Hisakazu Nishikawa, Masanori Ono, Yoshiaki Kanamori, Akira J Infect Chemother Original Article OBJECTIVES: We investigated relationships between subclinical COVID-19 (coronavirus disease 2019) and background factors. METHODS: We determined SARS-CoV-2 antibody (IgG) prevalence in 1603 patients, doctors, and nurses in 65 medical institutions in Kanagawa Prefecture, Japan and investigated their background factors. Antibodies (IgG) against SARS-CoV-2 were analyzed by Immunochromatographic test. RESULTS: The 39 subjects (2.4%) were found to be IgG antibody-positive: 29 in the patient group (2.9%), 10 in the doctor/nurse group (2.0%), and 0 in the control group. After adjustment for age, sex, and the antibody prevalence in the control group, antibody prevalence was 2.7% in the patient group and 2.1% in the doctor/nurse group. There was no significant difference between the antibody-positive subjects and the antibody-negative subjects in any background factors investigated including overseas travel, contact with overseas travelers, presence/absence of infected individuals in the living area, use of trains 5 times a week or more, BCG vaccination, and use of ACE inhibitor and ARB. CONCLUSIONS: Antibody prevalence in the present survey at medical institution is higher than that in Tokyo and in Osaka measured by the government suggesting that subclinical infections are occurring more frequently than expected. No background factor that influenced antibody-positive status due to subclinical infection was identified. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2020-12 2020-09-06 /pmc/articles/PMC7474902/ /pubmed/32958395 http://dx.doi.org/10.1016/j.jiac.2020.09.005 Text en © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Matsuba, Ikuro Hatori, Nobuo Koido, Norihiko Watanabe, Yoshiyuki Ebara, Futoshi Matsuzawa, Yoko Nishikawa, Tetsuo Kunishima, Tomoyuki Degawa, Hisakazu Nishikawa, Masanori Ono, Yoshiaki Kanamori, Akira Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) |
title | Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) |
title_full | Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) |
title_fullStr | Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) |
title_full_unstemmed | Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) |
title_short | Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) |
title_sort | survey of the current status of subclinical coronavirus disease 2019 (covid-19) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474902/ https://www.ncbi.nlm.nih.gov/pubmed/32958395 http://dx.doi.org/10.1016/j.jiac.2020.09.005 |
work_keys_str_mv | AT matsubaikuro surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT hatorinobuo surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT koidonorihiko surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT watanabeyoshiyuki surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT ebarafutoshi surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT matsuzawayoko surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT nishikawatetsuo surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT kunishimatomoyuki surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT degawahisakazu surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT nishikawamasanori surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT onoyoshiaki surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 AT kanamoriakira surveyofthecurrentstatusofsubclinicalcoronavirusdisease2019covid19 |